Robert McNamara - Jun 4, 2025 Form 4 Insider Report for AVITA Medical, Inc. (RCEL)

Role
Director
Signature
/s/ Nicole Kelsey, by power of attorney
Stock symbol
RCEL
Transactions as of
Jun 4, 2025
Transactions value $
$0
Form type
4
Date filed
6/5/2025, 04:50 PM
Previous filing
Mar 10, 2025
Next filing
Aug 20, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
McNamara Robert Director C/O AVITA MEDICAL 28159 AVENUE STANFORD, SUITE 220, VALENCIA /s/ Nicole Kelsey, by power of attorney 2025-06-05 0001387652

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCEL Common Stock Award +10K +17.66% 66.8K Jan 21, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RCEL Stock Options (Right to Buy) Award $0 +4.3K $0.00 4.3K Jan 21, 2025 Common Stock 4.3K $8.73 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 21, 2025. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.
F2 Includes unvested RSUs.
F3 On January 6, 2025, the Board of Directors approved a grant of 4,295 options to acquire 4,295 shares of Common Stock to each of its non-executive directors, with a grant date of January 21, 2025 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $8.73. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.